# Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis

> **NCT01308021** · PHASE2 · COMPLETED · sponsor: **BioTech Tools S.A.** · enrollment: 202 (actual)

## Conditions studied

- Grass Pollen Allergy
- Hay Fever

## Interventions

- **BIOLOGICAL:** gpASIT+TM
- **BIOLOGICAL:** gpASIT+TM
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01308021
- **Lead sponsor:** BioTech Tools S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-12
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2014-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308021, "Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01308021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*